Here’s What TD Cowen Thinks About Tempus AI Inc (TEM) Stock

Why It Matters

The upgrade signals renewed investor confidence in Tempus’s rapid revenue growth and its expanding foothold in the lucrative AI‑healthcare sector, especially in Japan.

Key Takeaways

• TD Cowen upgrades Tempus to Buy, price target $65
• 2025 revenue hit $1.3 billion, up 83.4%
• 2026 revenue forecast $1.59 billion, 25% growth
• SoftBank joint venture opens Japanese AI healthcare market
• Partnerships with Gilead and Merck boost drug development pipeline

Pulse Analysis

Tempus AI’s recent upgrade to a Buy rating reflects a broader shift in capital markets toward AI‑enabled precision medicine. The firm’s 83.4% revenue surge to $1.3 billion in 2025 outpaces most peers, driven by its Insights platform that aggregates clinical data to accelerate trial design. By forecasting $1.59 billion in 2026, Tempus signals a sustainable growth trajectory that aligns with investors’ appetite for high‑margin, data‑rich health tech businesses.

The strategic alliance with SoftBank, structured as a joint venture, positions Tempus at the forefront of Japan’s burgeoning AI‑healthcare market, projected to reach $2.29 billion by 2034. This partnership not only grants access to a vast patient pool but also leverages SoftBank’s capital and distribution network to scale AI‑driven treatment recommendations. Complementary collaborations with Gilead and Merck further embed Tempus’s technology into drug development pipelines, enhancing its credibility and creating multiple revenue streams beyond oncology, including cardiology and infectious diseases.

For investors, the downgrade in price target to $65 may appear contradictory, yet it reflects a more disciplined valuation after a 50% share decline. The lower target offers a margin of safety while preserving upside potential as the company capitalizes on its expanding partnership ecosystem and the global push toward personalized medicine. In a market where AI health startups often face regulatory and adoption hurdles, Tempus’s proven revenue growth and high‑profile alliances make it a compelling, albeit competitive, play in the AI‑driven healthcare landscape.